We recently published a list of 10 Small–Cap Stocks Insiders Are Selling Recently. In this article, we are going to take a look at where Travere Therapeutics, Inc. (NASDAQ:TVTX) stands against other ...

Entropy Technologies LP purchased a new stake in shares of Travere Therapeutics, Inc. (NASDAQ:TVTX – Free Report) during the ...

Travere Therapeutics (NASDAQ:TVTX – Free Report) had its price target hoisted by Evercore ISI from $33.00 to $45.00 in a research note released on Wednesday,Benzinga reports. The brokerage currently ...

Calvin Sandra, the Senior Vice President and Chief Accounting Officer at Travere Therapeutics, Inc. (NASDAQ:TVTX), executed a ...

Guggenheim analyst Vamil Divan raised the firm’s price target on Travere Therapeutics (TVTX) to $47 from $45 and keeps a Buy rating on the ...

Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced it will report fourth quarter and full year 2024 financial results on Thursday, February 20, 2025, after the close of the U.S. financial ...

Officer at Travere Therapeutics, Inc. (NASDAQ:TVTX), a $2 billion market cap biopharmaceutical company whose stock has surged 190% over the past year, recently sold 2,568 shares of the company's ...

Scotiabank analyst Greg Harrison maintained a Buy rating on Travere Therapeutics (TVTX – Research Report) today and set a price target of ...

Company completed Type C meeting with FDA, aligning on its plan to submit an sNDA; submission expected around end of 1Q25 If approved, FILSPARI could be the first and only approved medicine indicated ...